抗病毒治疗后乙肝核心抗原与表面抗原表达变化及其在慢性乙肝预后中的作用
该研究分析了HBeAg阳性和阴性慢性乙肝患者接受4年核苷(酸)类似物(NA)治疗前后的肝活检免疫组化,发现治疗后无HBcAg染色比例从26%升至63%,而无HBsAg染色比例仅从14%升至26%;HBcAg染色减少与病毒复制抑制相关,HBsAg染色范围变化有限,可能反映整合HBV DNA产生HBsAg。
要点
- 长期NA治疗显著减少HBcAg表达,但与HBsAg表达范围变化有限。
- HBcAg染色消失与病毒复制抑制持续时间相关。
- 无连续性颗粒状HBsAg模式与HBsAg清除相关。
核心结论
- NA治疗抑制病毒复制与HBcAg表达显著减少相关,而HBsAg表达范围变化有限,可能反映整合HBV DNA产生HBsAg。
主要发现
- 治疗前四分之三患者HBcAg阳性,主要为胞质染色模式,86%可检测到HBsAg,其中79%呈散在颗粒状。
- 4年NA治疗后,无HBcAg染色活检比例从26%升至63%,无HBsAg染色比例从14%升至26%。
- 病毒复制抑制与HBcAg染色显著下降相关,HBcAg染色消失与复制抑制持续时间相关。
- 长期NA治疗对HBsAg染色范围影响甚微,无连续性颗粒状HBsAg模式与HBsAg清除相关。
临床怎么用
- 肝组织HBcAg和HBsAg免疫染色可用于评估NA治疗后的病毒抗原表达变化。
- HBcAg染色减少可反映病毒复制抑制,但HBsAg表达持续可能提示整合HBV DNA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatitis B core antigen (HBcAg) and surface antigen (HBsAg) can be detected through immunostaining of liver tissue. This study examined the extent and patterns of HBcAg and HBsAg staining before and after long-term nucleos(t)ide analogue (NA) therapy. METHODS: Liver biopsies performed before and after 4 years of NA treatment were analyzed from patients with HBeAg-positive and HBeAg-negative chronic hepatitis B participating in 3 treatment trials. Immunostaining for HBcAg and HBsAg was evaluated using semiquantitative scales for both extent and distribution. HBV DNA, HBV RNA, HBeAg status, and quantitative HBsAg (qHBsAg) were correlated with changes in immunostaining. Baseline HBcAg and HBsAg staining were correlated with clinical outcomes. RESULTS: Ninety-one patients had a pretreatment biopsy, and 81 had paired pretreatment and year 4 biopsies. Pretreatment, three-quarters were positive for HBcAg, predominantly in a cytoplasmic staining pattern, and 86% had detectable HBsAg, with 79% exhibiting a scattered granular pattern. Following 4 years of NA treatment, the proportion of biopsies without HBcAg staining increased from 26% to 63% and HBsAg staining from 14% to 26% compared with baseline. Inhibition of replication was associated with a significant decline in HBcAg staining, and loss of HBcAg staining was related to the duration of replication inhibition. In contrast, long-term NA therapy had minimal effect on the extent of HBsAg staining. The absence of contiguous granular HBsAg pattern was associated with HBsAg loss. CONCLUSIONS: NA-related inhibition of viral replication was associated with marked reduction in HBcAg expression in HBeAg-positive and HBeAg-negative patients but minimal changes in extent of HBsAg staining, likely reflecting HBsAg production from integrated HBV DNA.
引用
- Shaik MR, Apodaca L, Auh S, et al. Changes in Hepatitis B Core Antigen and Hepatitis B Surface Antigen Expression Following Antiviral Therapy and Their Role in Outcome of Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2025. PMID: 41077235. doi:10.1016/j.cgh.2025.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。